Drug Trial Radar · NCT02024646
Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis
Last checked: Nov 20, 2026Latest source record: Aug 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
484
Actual
Start
Mar 2014
Primary completion
Oct 2015
Study completion Oct 2015
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 31, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis. The key secondary objective is to evaluate the efficacy of brodalumab compared to placebo at week 16. The safety objective of this study is to evaluate the safety profile of brodalumab in subjects with psoriatic arthritis.
Conditions
- Psoriatic Arthritis
Interventions
210 mg brodalumabDrug
210 mg brodalumab administered via subcutaneous injection.
140 mg brodalumabDrug
140 mg brodalumab administered via subcutaneous injection.
PlaceboDrug
Placebo administered via subcutaneous injection until week 24.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ACR20 (American College of Rheumatology 20% Improvement) Response Rate Through Week 16Time frame: Baseline and 16 Weeks
Locations
103 sites in 10 countries. Site status is shown where the registry gives one.
Research Site
Peoria, Arizona
Research Site
Little Rock, Arkansas
Research Site
Cypress, California
Research Site
Hemet, California
Research Site
Huntington Beach, California
Research Site
La Jolla, California
Research Site
Palm Desert, California
Research Site
Palo Alto, California
Research Site
Victorville, California
Research Site
Sarasota, Florida
Research Site
St. Petersburg, Florida
Research Site
Tampa, Florida
Research Site
Tampa, Florida
Research Site
Chicago, Illinois
Research Site
Paducah, Kentucky
Research Site
Baton Rouge, Louisiana
Research Site
Wheaton, Maryland
Research Site
Boston, Massachusetts
Research Site
Battle Creek, Michigan
Research Site
Grand Rapids, Michigan
Research Site
Lansing, Michigan
Research Site
St Louis, Missouri
Research Site
Las Vegas, Nevada
Research Site
Rochester, New York
Research Site
Oklahoma City, Oklahoma
Research Site
Tulsa, Oklahoma
Research Site
Dallas, Texas
Research Site
Dallas, Texas
Research Site
Waco, Texas
Research Site
Chesapeake, Virginia
Research Site
Seattle, Washington
Research Site
Calgary, Alberta, Canada
Research Site
Victoria, British Columbia, Canada
Research Site
Winnipeg, Manitoba, Canada
Research Site
St. John's, Newfoundland and Labrador, Canada
Research Site
St. John's, Newfoundland and Labrador, Canada
Research Site
Waterloo, Ontario, Canada
Research Site
Québec, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Trois-Rivières, Quebec, Canada
Showing 40 of 103 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.